Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Robert Wasserman
BENC
Robert Wasserman
Wall Street Analyst
★☆☆☆☆
#2468
on 13Foresight · ranked by our own returns
43%
Success Rate
-14.6%
Average Return
12 of 28 calls profitable · -38.3% vs benchmark
📈 Across the calls we could measure, roughly 43% of Robert Wasserman's ratings turned a profit when each position was held for 2 year — averaging -14.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

28 Buy 6 Hold 0 Sell
Robert's Stock Coverage 30 ratings · 2026-06-19
Company Date Position Consensus Price Target 2-Yr Return
PRLB
Proto Labs
Jun 08, 2026 BUY Buy
-16.5% avg upside
11 analysts
$70.00
13.57% Downside
·
XOMA
XOMA Royalty Corporation
May 22, 2026 HOLD Buy
-46.4% avg upside
11 analysts
+0.1%
ITGR
Integer Holdings
Feb 20, 2026 BUY Buy
+6.6% avg upside
15 analysts
$95.00
4.50% Upside
+6.6%
HALO
Halozyme
Feb 19, 2026 BUY Strong Buy
-13.7% avg upside
20 analysts
$90.00
31.29% Upside
-4.8%
IL:KMDA
Kamada
Jan 08, 2026 BUY Strong Buy
+74.5% avg upside
7 analysts
$4373.55
104.59% Upside
·
LGND
Ligand Pharma
Dec 10, 2025 BUY Strong Buy
-20.8% avg upside
15 analysts
$220.00
19.96% Downside
+43.0%
CDXS
Codexis
Nov 14, 2025 HOLD Strong Buy
+291.5% avg upside
13 analysts
+49.1%
OABI
OmniAb
Nov 06, 2025 BUY Strong Buy
+249.1% avg upside
10 analysts
$4.00
71.02% Upside
+65.2%
INTS
Intensity Therapeutics, Inc.
Oct 31, 2025 BUY Strong Buy
+1441.3% avg upside
6 analysts
$37.50
856.60% Upside
-74.6%
RGEN
Repligen
Oct 29, 2025 HOLD Strong Buy
+28.3% avg upside
25 analysts
-17.6%
ABCL
AbCellera Biologics
Aug 13, 2025 HOLD Strong Buy
+139.4% avg upside
15 analysts
-3.7%
NEPH
Nephros
Aug 12, 2025 BUY Strong Buy
+106.4% avg upside
2 analysts
$5.00
58.73% Upside
-13.6%
BLFS
BioLife Solutions
Aug 11, 2025 BUY Strong Buy
+13.0% avg upside
17 analysts
$30.00
15.16% Upside
+7.1%
EBS
Emergent Biosolutions
Aug 08, 2025 BUY Buy
+217.0% avg upside
9 analysts
$12.00
49.93% Upside
-6.7%
TECH
Bio-Techne
Aug 07, 2025 BUY Strong Buy
+38.6% avg upside
21 analysts
$75.00
29.43% Upside
+12.4%
HYFT
MindWalk Holdings
Jul 31, 2025 BUY Strong Buy
+183.2% avg upside
3 analysts
$3.00
96.07% Upside
-28.3%
ANEB
Anebulo Pharmaceuticals
May 22, 2025 BUY Buy
+796.5% avg upside
5 analysts
$3.00
668.48% Upside
-58.6%
ATHE
Alterity Therapeutics
Feb 03, 2025 HOLD Strong Buy
+68.0% avg upside
5 analysts
$4.00
18.08% Downside
-21.8%
TMO
Thermo Fisher
Oct 26, 2023 HOLD Strong Buy
+26.9% avg upside
38 analysts
+30.9%
DHR
Danaher
Oct 25, 2023 HOLD Strong Buy
+21.8% avg upside
45 analysts
+17.0%
CSBR
Champions Oncology
Sep 15, 2023 HOLD Strong Buy
+34.6% avg upside
6 analysts
+58.1%
PCSA
Processa Pharmaceuticals
Apr 04, 2023 BUY Strong Buy
+1996.9% avg upside
5 analysts
$80.00
3673.65% Upside
-96.5%
FBIO
Fortress Biotech
Feb 24, 2021 BUY Strong Buy
+163.3% avg upside
12 analysts
$9.00
201.02% Upside
-83.0%
CVM
Cel-Sci
Jan 24, 2020 HOLD Hold
2 analysts
-55.8%
FEED
ENvue Medical Inc
Jan 09, 2019 BUY Strong Buy
+1463.6% avg upside
1 analyst
$10.50
1463.60% Upside
-73.7%
IDXG
Interpace Diagnostics Group
Oct 17, 2018 BUY Strong Buy
+617.5% avg upside
9 analysts
$4.20
152.04% Upside
·
NUWE
Nuwellis
Aug 28, 2018 BUY Strong Buy
+16826.0% avg upside
7 analysts
$46.20
34506.71% Upside
-97.9%
GRCE
Grace Therapeutics
Jan 29, 2018 BUY Strong Buy
+153.0% avg upside
9 analysts
-35.0%
XWEL
XWELL
Nov 07, 2013 BUY Buy
+372.6% avg upside
4 analysts
$5.25
341.12% Upside
-88.4%
AGEN
Agenus
Mar 12, 2013 BUY Strong Buy
+165.3% avg upside
17 analysts
$6.00
100.08% Upside
+27.0%
🔒 25 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Robert Wasserman — Frequently Asked Questions
How accurate are Robert Wasserman's stock ratings?
Based on the calls 13Foresight could measure, about 39% of Robert's ratings were profitable over a one-year hold, with an average return of -10.4% per rating, or -27.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Robert ranked on 13Foresight?
Robert Wasserman is currently ranked #2468 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Robert cover?
Robert most recently has ratings on PRLB, XOMA, ITGR, HALO, IL:KMDA, LGND, CDXS, OABI, INTS, RGEN, ABCL, NEPH and 18 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.